Effect of Dupilumab on Blood Eosinophil ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Permalink :
Title :
Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis.
Author(s) :
Wechsler, Michael E. [Auteur]
Klion, Amy D. [Auteur]
Paggiaro, Pierluigi [Auteur]
Nair, Parameswaran [Auteur]
staumont, delphine [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Radwan, Amr [Auteur]
Johnson, Robert R. [Auteur]
Kapoor, Upender [Auteur]
Khokhar, Faisal A. [Auteur]
Daizadeh, Nadia [Auteur]
Chen, Zhen [Auteur]
Laws, Elizabeth [Auteur]
Ortiz, Benjamin [Auteur]
Jacob-Nara, Juby A. [Auteur]
Mannent, Leda P. [Auteur]
Sanofi Aventis R&D [Chilly-Mazarin]
Rowe, Paul J. [Auteur]
Deniz, Yamo [Auteur]
Klion, Amy D. [Auteur]
Paggiaro, Pierluigi [Auteur]
Nair, Parameswaran [Auteur]
staumont, delphine [Auteur]

Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Radwan, Amr [Auteur]
Johnson, Robert R. [Auteur]
Kapoor, Upender [Auteur]
Khokhar, Faisal A. [Auteur]
Daizadeh, Nadia [Auteur]
Chen, Zhen [Auteur]
Laws, Elizabeth [Auteur]
Ortiz, Benjamin [Auteur]
Jacob-Nara, Juby A. [Auteur]
Mannent, Leda P. [Auteur]
Sanofi Aventis R&D [Chilly-Mazarin]
Rowe, Paul J. [Auteur]
Deniz, Yamo [Auteur]
Journal title :
The Journal of Allergy and Clinical Immunology: In Practice
Abbreviated title :
J Allergy Clin Immunol Pract
Volume number :
10
Pages :
P2695-2709
Publication date :
2022-06-04
ISSN :
2213-2201
English keyword(s) :
Eosinophils
Eosinophilic esophagitis
Eosinophilia
Dupilumab
Chronic rhinosinusitis with nasal polyps
Atopic dermatitis
Asthma
Eosinophilic esophagitis
Eosinophilia
Dupilumab
Chronic rhinosinusitis with nasal polyps
Atopic dermatitis
Asthma
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Background
Transient increases in blood eosinophil counts have been observed in dupilumab clinical trials.
Objective
To assess eosinophil counts and eosinophilia-related treatment-emergent adverse events (TEAEs) across ...
Show more >Background Transient increases in blood eosinophil counts have been observed in dupilumab clinical trials. Objective To assess eosinophil counts and eosinophilia-related treatment-emergent adverse events (TEAEs) across 11 dupilumab clinical trials, comparing adult and adolescent patients with asthma and adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP), atopic dermatitis, and eosinophilic esophagitis. Methods Eosinophil counts, rates of eosinophilia-related TEAEs or treatment-emergent eosinophilia (>1,500 cells/μL), discontinuations, clinical symptoms, and efficacy in patients with asthma or CRSwNP with treatment-emergent eosinophilia are presented. Results Transient increases in mean eosinophil counts were observed in dupilumab-treated patients with asthma (mean range across studies at baseline: 349-370 cells/μL; week 4: 515-578 cells/μL), CRSwNP (baseline: 440-448 cells/μL; week 16: 595 cells/μL), and atopic dermatitis (baseline: 434-600 cells/μL; week 4: 410-710 cells/μL), followed by a decline starting by week 24 to baseline or lower. No increases were seen in patients with eosinophilic esophagitis (baseline: 310 cells/μL; week 4: 230 cells/μL). In dupilumab-treated patients across all studies, rates of eosinophilia TEAEs were 0% to 13.6%. Clinical symptoms associated with increased eosinophils were rare (seven of 4,666 dupilumab-treated patients, including six cases of eosinophilic granulomatosis with polyangiitis) and occurred only in patients with asthma or CRSwNP. Eosinophilia was not associated with reduced dupilumab efficacy. Conclusions Transient increases in eosinophil counts with dupilumab treatment did not affect efficacy and were rarely of clinical consequence. It remains important for physicians to base judgment on individual patient history and baseline eosinophil counts and to be alert to hypereosinophilic symptoms.Show less >
Show more >Background Transient increases in blood eosinophil counts have been observed in dupilumab clinical trials. Objective To assess eosinophil counts and eosinophilia-related treatment-emergent adverse events (TEAEs) across 11 dupilumab clinical trials, comparing adult and adolescent patients with asthma and adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP), atopic dermatitis, and eosinophilic esophagitis. Methods Eosinophil counts, rates of eosinophilia-related TEAEs or treatment-emergent eosinophilia (>1,500 cells/μL), discontinuations, clinical symptoms, and efficacy in patients with asthma or CRSwNP with treatment-emergent eosinophilia are presented. Results Transient increases in mean eosinophil counts were observed in dupilumab-treated patients with asthma (mean range across studies at baseline: 349-370 cells/μL; week 4: 515-578 cells/μL), CRSwNP (baseline: 440-448 cells/μL; week 16: 595 cells/μL), and atopic dermatitis (baseline: 434-600 cells/μL; week 4: 410-710 cells/μL), followed by a decline starting by week 24 to baseline or lower. No increases were seen in patients with eosinophilic esophagitis (baseline: 310 cells/μL; week 4: 230 cells/μL). In dupilumab-treated patients across all studies, rates of eosinophilia TEAEs were 0% to 13.6%. Clinical symptoms associated with increased eosinophils were rare (seven of 4,666 dupilumab-treated patients, including six cases of eosinophilic granulomatosis with polyangiitis) and occurred only in patients with asthma or CRSwNP. Eosinophilia was not associated with reduced dupilumab efficacy. Conclusions Transient increases in eosinophil counts with dupilumab treatment did not affect efficacy and were rarely of clinical consequence. It remains important for physicians to base judgment on individual patient history and baseline eosinophil counts and to be alert to hypereosinophilic symptoms.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
Université de Lille
Inserm
CHU Lille
Inserm
CHU Lille
Submission date :
2024-01-12T01:22:50Z
2024-02-05T07:53:16Z
2024-02-05T07:53:16Z
Files
- PIIS2213219822005074.pdf
- Non spécifié
- Open access
- Access the document
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States